Cited 104 times in
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 백순명 | - |
dc.date.accessioned | 2016-02-04T11:52:38Z | - |
dc.date.available | 2016-02-04T11:52:38Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/141399 | - |
dc.description.abstract | PURPOSE: Considerable molecular heterogeneity exists among human epidermal growth factor receptor 2 (HER2) -positive breast cancer regarding gene expression and mutation profiling. Evidence from preclinical, clinical neoadjuvant, and metastatic clinical trials suggested that PIK3CA mutational status and PAM50 intrinsic subtype of a tumor were markers of response to anti-HER2 therapies. We evaluated the predictive value of these two biomarkers in the adjuvant setting using archived tumor blocks from National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31. PATIENTS AND METHODS: Expression data for 49 genes using the nCounter platform were used to generate PAM50 intrinsic subtypes for 1,578 archived tumor blocks from patients in the B-31 trial. Six PIK3CA hotspot mutations were examined by mass spectrometry of the primer extension products in a randomly selected subset (n = 671). We examined the heterogeneity of trastuzumab treatment effect across different subsets defined by each marker using Cox regression and disease-free survival as the end point. RESULTS: Seven hundred forty-one (47.0%) of 1,578 tumors were classified as HER2-enriched (HER2E) subtype, and 166 (24.7%) of 671 tumors had PIK3CA mutations. Hazard ratios (HRs) for trastuzumab in HER2E and other subtypes were 0.44 (95% CI, 0.34 to 0.58; P < .001) and 0.47 (95% CI, 0.35 to 0.62; P < .001), respectively (interaction P = .67). HRs for trastuzumab in PIK3CA wild-type and mutated tumors were 0.51 (95% CI, 0.37 to 0.71; P < .001) and 0.44 (95% CI, 0.24 to 0.82; P = .009), respectively (interaction P = .64). CONCLUSION: Unlike results seen in the metastatic and neoadjuvant clinical trials, PIK3CA and PAM50 intrinsic subtypes were not predictive biomarkers for adjuvant trastuzumab in NSABP B-31. These data suggest that results from the metastatic and neoadjuvant setting may not be always applicable to the adjuvant setting. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1340~1347 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Life Science (의생명과학부) | - |
dc.contributor.googleauthor | Katherine L. Pogue-Geile | - |
dc.contributor.googleauthor | Nan Song | - |
dc.contributor.googleauthor | Jong-Hyeon Jeong | - |
dc.contributor.googleauthor | Patrick G. Gavin | - |
dc.contributor.googleauthor | Seong-Rim Kim | - |
dc.contributor.googleauthor | Nicole L. Blackmon | - |
dc.contributor.googleauthor | Melanie Finnigan | - |
dc.contributor.googleauthor | Priya Rastogi | - |
dc.contributor.googleauthor | Louis Fehrenbacher | - |
dc.contributor.googleauthor | Eleftherios P. Mamounas | - |
dc.contributor.googleauthor | Sandra M. Swain | - |
dc.contributor.googleauthor | D. Lawrence Wickerham | - |
dc.contributor.googleauthor | Charles E. Geyer | - |
dc.contributor.googleauthor | Joseph P. Costantino | - |
dc.contributor.googleauthor | Norman Wolmark | - |
dc.contributor.googleauthor | Soonmyung Paik | - |
dc.identifier.doi | 10.1200/JCO.2014.56.2439 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01823 | - |
dc.relation.journalcode | J01331 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.url | http://jco.ascopubs.org/content/33/12/1340.abstract | - |
dc.contributor.alternativeName | Paik, Soon Myung | - |
dc.contributor.affiliatedAuthor | Paik, Soon Myung | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 33 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1340 | - |
dc.citation.endPage | 1347 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, Vol.33(12) : 1340-1347, 2015 | - |
dc.identifier.rimsid | 30622 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.